Text Size

Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy

This study has been completed.
Sponsor:
Collaborator:
Napoli CTO Hospital
Information provided by:
Second University of Naples
ClinicalTrials.gov Identifier:
NCT01025934
First received: December 3, 2009
Last updated: NA
Last verified: December 2009
History: No changes posted
  Purpose

The purpose of this study is to evaluate the role, the safety and the effectiveness of Intravitreal Bevacizumab injections as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy.


Condition Intervention Phase
Proliferative Diabetic Retinopathy
 Drug: Bevacizumab
Other: sham
 Phase 4

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy

Resource links provided by NLM:

Drug Information available for: Bevacizumab
U.S. FDA Resources

Further study details as provided by Second University of Naples:

Arms Assigned Interventions
Active Comparator: 7 days Drug: Bevacizumab
Active Comparator: 20 days Drug: Bevacizumab
Sham Comparator: sham Other: sham

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • vitreous haemorrhage
  • tractional retinal detachment
  • active proliferative diabetic retinopathy.

Exclusion Criteria:

  • neovascular glaucoma
  • cataract
  • combined traction and rhegmatogenous RD
  Contacts and Locations
No Contacts or Locations Provided
  More Information

No publications provided by Second University of Naples

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

ClinicalTrials.gov Identifier: NCT01025934     History of Changes
Other Study ID Numbers: IVBDRNA
Study First Received: December 3, 2009
Last Updated: December 3, 2009
Health Authority: Italy: Ethics Committee

Additional relevant MeSH terms:
Diabetic Retinopathy
Retinal Diseases
Eye Diseases
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
 Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Growth Inhibitors
Antineoplastic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 16, 2013